Latest News & Features
article
Managing partner oversees a varied range of global patent portfolios, often acting as the ‘in-house’ attorney for multinational clients. 2 January 2024
Big Pharma
CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech. 21 December 2023
Biotechnology
Medical device company wins eight-day jury trial in spinal implant patent dispute | Johns Hopkins neurosurgeon claimed Globus Medical directly infringed multiple patents in US | Susman Godfrey | Fish & Richardson. 19 December 2023
Big Pharma
The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation. 19 December 2023
Biotechnology
Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines. 14 December 2023
Genetics
Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021. 14 December 2023
Big Pharma
Court rules that patent must be later-filed to be available as OTDP reference | MSN had submitted ANDA for generic version of Parkinson’s treatment Nuplazid. 14 December 2023
Big Pharma
US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights. 12 December 2023
Big Pharma
Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 12 December 2023
Big Pharma
Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar. 7 December 2023